| Date of report (Date of earliest event reported): | |||||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
| Registrant’s telephone number, including area code: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Number | Description | ||||
| 99.1 | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
INTERNATIONAL FLAVORS & FRAGRANCES INC. | |||||
| By: | /s/ Glenn Richter | ||||
| Name: | Glenn Richter | ||||
| Title: | Executive Vice President and Chief Financial & Business Transformation Officer | ||||
| Dated: | February 27, 2023 | ||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||
| 2022 | 2021 | % Change | 2022 | 2021 | % Change | ||||||||||||||||||||||||||||||
| Net sales | $ | 2,844 | $ | 3,031 | (6) | % | $ | 12,440 | $ | 11,656 | 7 | % | |||||||||||||||||||||||
| Cost of goods sold | 1,975 | 2,050 | (4) | % | 8,289 | 7,921 | 5 | % | |||||||||||||||||||||||||||
| Gross profit | 869 | 981 | (11) | % | 4,151 | 3,735 | 11 | % | |||||||||||||||||||||||||||
| Research and development expenses | 143 | 166 | (14) | % | 603 | 629 | (4) | % | |||||||||||||||||||||||||||
| Selling and administrative expenses | 440 | 450 | (2) | % | 1,768 | 1,749 | 1 | % | |||||||||||||||||||||||||||
| Restructuring and other charges | 7 | 7 | — | % | 12 | 41 | (71) | % | |||||||||||||||||||||||||||
| Amortization of acquisition-related intangibles | 175 | 185 | (5) | % | 727 | 732 | (1) | % | |||||||||||||||||||||||||||
| Impairment of goodwill | — | — | NMF | 2,250 | — | NMF | |||||||||||||||||||||||||||||
| Impairment of long-lived assets | — | — | NMF | 120 | — | NMF | |||||||||||||||||||||||||||||
| Gains on sale of fixed assets | (1) | — | NMF | (3) | (1) | 200 | % | ||||||||||||||||||||||||||||
| Operating profit (loss) | 105 | 173 | (39) | % | (1,326) | 585 | NMF | ||||||||||||||||||||||||||||
| Interest expense | 104 | 73 | 42 | % | 336 | 289 | 16 | % | |||||||||||||||||||||||||||
| Other expense (income), net | 6 | (14) | (143) | % | (37) | (58) | (36) | % | |||||||||||||||||||||||||||
| (Loss) income before taxes | (5) | 114 | (104) | % | (1,625) | 354 | NMF | ||||||||||||||||||||||||||||
| Provision for income taxes | 19 | 22 | (14) | % | 239 | 75 | 219 | % | |||||||||||||||||||||||||||
| Net (loss) income | (24) | 92 | (126) | % | (1,864) | 279 | NMF | ||||||||||||||||||||||||||||
| Net income attributable to non-controlling interest | 1 | 2 | (50) | % | 7 | 9 | (22) | % | |||||||||||||||||||||||||||
| Net (loss) income attributable to IFF shareholders | $ | (25) | $ | 90 | (128) | % | $ | (1,871) | $ | 270 | NMF | ||||||||||||||||||||||||
Net (loss) income per share - basic (1) | $ | (0.10) | $ | 0.35 | $ | (7.32) | $ | 1.11 | |||||||||||||||||||||||||||
Net (loss) income per share - diluted (1) | $ | (0.10) | $ | 0.35 | $ | (7.32) | $ | 1.10 | |||||||||||||||||||||||||||
| Average number of shares outstanding - basic | 255 | 255 | 255 | 243 | |||||||||||||||||||||||||||||||
| Average number of shares outstanding - diluted | 255 | 255 | 255 | 243 | |||||||||||||||||||||||||||||||
| December 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| Cash, cash equivalents and restricted cash | $ | 493 | $ | 715 | |||||||
| Receivables, net | 1,818 | 1,906 | |||||||||
| Inventories | 3,151 | 2,516 | |||||||||
| Other current assets | 1,970 | 1,850 | |||||||||
| Total current assets | 7,432 | 6,987 | |||||||||
| Property, plant and equipment, net | 4,203 | 4,368 | |||||||||
| Goodwill and other intangibles, net | 22,437 | 26,920 | |||||||||
| Other assets | 1,335 | 1,383 | |||||||||
| Total assets | $ | 35,407 | $ | 39,658 | |||||||
| Short-term borrowings | $ | 597 | $ | 632 | |||||||
| Other current liabilities | 3,131 | 3,001 | |||||||||
| Total current liabilities | 3,728 | 3,633 | |||||||||
| Long-term debt | 10,373 | 10,768 | |||||||||
| Non-current liabilities | 3,533 | 4,035 | |||||||||
| Redeemable non-controlling interests | 59 | 105 | |||||||||
| Shareholders' equity | 17,714 | 21,117 | |||||||||
| Total liabilities and shareholders' equity | $ | 35,407 | $ | 39,658 | |||||||
| Year Ended December 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net (loss) income | $ | (1,864) | $ | 279 | |||||||
| Adjustments to reconcile to net cash provided by operations: | |||||||||||
| Depreciation and amortization | 1,179 | 1,156 | |||||||||
| Deferred income taxes | (237) | (236) | |||||||||
| (Gains) losses on sale of fixed assets | (3) | (1) | |||||||||
| Gains on business divestiture | (11) | — | |||||||||
| Stock-based compensation | 49 | 54 | |||||||||
| Pension contributions | (36) | (37) | |||||||||
| Amortization of inventory step-up | — | 368 | |||||||||
| Impairment of goodwill | 2,250 | — | |||||||||
| Impairment of long-lived assets | 120 | — | |||||||||
| Changes in assets and liabilities, net of acquisitions: | |||||||||||
| Trade receivables | (117) | (169) | |||||||||
| Inventories | (893) | (363) | |||||||||
| Accounts payable | (57) | 419 | |||||||||
| Accruals for incentive compensation | (34) | 96 | |||||||||
| Other current payables and accrued expenses | 92 | 4 | |||||||||
| Other assets/liabilities, net | (41) | (133) | |||||||||
| Net cash provided by operating activities | 397 | 1,437 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Cash paid for acquisitions, net of cash received | (110) | — | |||||||||
| Additions to property, plant and equipment | (504) | (393) | |||||||||
| Additions to intangible assets | (2) | (4) | |||||||||
| Proceeds from disposal of assets | 8 | 18 | |||||||||
| Proceeds from unwinding of derivative instruments | 173 | — | |||||||||
| Cash provided by the Merger with N&B | 11 | 246 | |||||||||
| Net proceeds received from business divestiture | 1,169 | 115 | |||||||||
| Net cash provided by (used in) investing activities | 745 | (18) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Cash dividends paid to shareholders | (810) | (667) | |||||||||
| Dividends paid to redeemable non-controlling interest | — | (2) | |||||||||
| Increase (decrease) in revolving credit facility and short term borrowings | 104 | (105) | |||||||||
| Proceeds from issuance of commercial paper (maturities after three months) | 225 | — | |||||||||
| Repayments of commercial paper (maturities after three months) | (421) | — | |||||||||
| Net borrowings of commercial paper (maturities less than three months) | 48 | 324 | |||||||||
| Deferred financing costs | — | (3) | |||||||||
| Repayments of long-term debt | (300) | (828) | |||||||||
| Purchases of redeemable non-controlling interest | (47) | — | |||||||||
| Proceeds from issuance of long-term debt | — | 3 | |||||||||
| Contingent consideration paid | — | (14) | |||||||||
| Proceeds from issuance of stock in connection with stock options | — | 9 | |||||||||
| Employee withholding taxes paid | (21) | (21) | |||||||||
| Other, net | (7) | — | |||||||||
| Net cash used in financing activities | (1,229) | (1,304) | |||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (77) | (59) | |||||||||
| Net change in cash, cash equivalents and restricted cash | (164) | 56 | |||||||||
| Cash, cash equivalents and restricted cash at beginning of year | 716 | 660 | |||||||||
| Cash, cash equivalents and restricted cash at end of year | $ | 552 | $ | 716 | |||||||
| AMOUNTS IN MILLIONS | December 31, 2022 | December 31, 2021 | December 31, 2020 | ||||||||||||||
| Current assets | |||||||||||||||||
| Cash and cash equivalents | $ | 483 | $ | 711 | $ | 650 | |||||||||||
| Cash and cash equivalents included in Assets held for sale | 52 | — | — | ||||||||||||||
| Restricted cash | 10 | 4 | 7 | ||||||||||||||
| Non-current assets | |||||||||||||||||
| Restricted cash included in Other assets | 7 | 1 | 3 | ||||||||||||||
| Cash, cash equivalents and restricted cash | $ | 552 | $ | 716 | $ | 660 | |||||||||||
| Reconciliation of Net (Loss) Income and EPS | |||||||||||||||||||||||||||||||||||||||||||||||
| Fourth Quarter | |||||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
| (DOLLARS IN MILLIONS) | (Loss) income before taxes | Provision for (Benefit from) income taxes (i) | Net (loss) income attributable to IFF (j) | Diluted EPS (k) | Income before taxes | Provision for income taxes (i) | Net income attributable to IFF (j) | Diluted EPS | |||||||||||||||||||||||||||||||||||||||
| Reported (GAAP) | $ | (5) | $ | 19 | $ | (25) | $ | (0.10) | $ | 114 | $ | 22 | $ | 90 | $ | 0.35 | |||||||||||||||||||||||||||||||
| Acquisition Related Costs (a) | (6) | (1) | (5) | (0.02) | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Restructuring and Other Charges | 7 | 1 | 6 | 0.02 | 7 | 2 | 5 | 0.02 | |||||||||||||||||||||||||||||||||||||||
| Losses (Gains) on Sale of Fixed Assets | (1) | — | (1) | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Business Divestiture Costs (b) | 19 | (67) | 86 | 0.34 | 21 | 5 | 16 | 0.06 | |||||||||||||||||||||||||||||||||||||||
| Gains on Business Disposal | 3 | 14 | (11) | (0.04) | (13) | (14) | 1 | 0.01 | |||||||||||||||||||||||||||||||||||||||
| Employee Separation Costs (c) | 7 | — | 7 | 0.03 | 1 | — | 1 | — | |||||||||||||||||||||||||||||||||||||||
| Strategic Initiative Costs (d) | 3 | 1 | 2 | 0.01 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Global Shared Services Implementation Costs (e) | 4 | 1 | 3 | 0.01 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Pension Settlement (f) | — | — | — | — | 2 | — | 2 | 0.01 | |||||||||||||||||||||||||||||||||||||||
| Frutarom Acquisition Related Costs (g) | — | — | — | — | 2 | — | 2 | 0.01 | |||||||||||||||||||||||||||||||||||||||
| N&B Inventory Step-Up Costs | — | — | — | — | 5 | — | 5 | 0.02 | |||||||||||||||||||||||||||||||||||||||
| Integration Related Costs (h) | 21 | 5 | 16 | 0.07 | 25 | 6 | 19 | 0.07 | |||||||||||||||||||||||||||||||||||||||
| Adjusted (Non-GAAP) | $ | 52 | $ | (27) | $ | 78 | $ | 0.31 | $ | 164 | $ | 21 | $ | 141 | $ | 0.55 | |||||||||||||||||||||||||||||||
| Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization | |||||||||||
| Fourth Quarter | |||||||||||
| (DOLLARS AND SHARE AMOUNTS IN MILLIONS) | 2022 | 2021 | |||||||||
| Numerator | |||||||||||
| Adjusted (Non-GAAP) Net Income | $ | 78 | $ | 141 | |||||||
| Amortization of Acquisition related Intangible Assets | 175 | 185 | |||||||||
| Tax impact on Amortization of Acquisition related Intangible Assets (i) | 40 | 45 | |||||||||
| Amortization of Acquisition related Intangible Assets, net of tax (l) | 135 | 140 | |||||||||
| Adjusted (Non-GAAP) Net Income ex. Amortization | $ | 213 | $ | 281 | |||||||
| Denominator | |||||||||||
| Weighted average shares assuming dilution (diluted) | 255 | 255 | |||||||||
| Adjusted (Non-GAAP) EPS ex. Amortization | $ | 0.83 | $ | 1.10 | |||||||
| (a) | Represents costs related to the acquisition of Health Wright Products, primarily consulting and legal fees, offset in part by earn out adjustments. | ||||||||||||||||||||||||||||||||||||||||||||||
| (b) | Represents costs, including establishment of deferred tax liabilities, related to the Company's sales and planned sales of businesses, primarily legal and professional fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (c) | Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company. | ||||||||||||||||||||||||||||||||||||||||||||||
| (d) | Represents costs related to the Company's strategic assessment and business portfolio optimization efforts, primarily consulting fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (e) | Represents costs related to the Company's efforts of restructuring the Global Shared Services Centers, primarily consulting fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (f) | Represents pension settlement charges incurred in one of the Company's UK pension plans. | ||||||||||||||||||||||||||||||||||||||||||||||
| (g) | Represents transaction-related costs and expenses related to the acquisition of Frutarom, primarily includes earn-out payments, net of adjustments. | ||||||||||||||||||||||||||||||||||||||||||||||
| (h) | Represents costs related to integration activities since 2018, primarily for Frutarom and N&B. For 2022, represents costs primarily related to external consulting fees and internal integration costs, including salaries of individuals who are fully dedicated to integration efforts. For 2021, represents costs primarily related to performance stock awards and consulting fees for advisory services. | ||||||||||||||||||||||||||||||||||||||||||||||
| (i) | The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments. | ||||||||||||||||||||||||||||||||||||||||||||||
| (j) | For 2022, net loss is increased by income attributable to non-controlling interest of $1 million. For 2021, net income is reduced by income attributable to non-controlling interest of $2 million. | ||||||||||||||||||||||||||||||||||||||||||||||
| (k) | The sum of these items does not foot due to rounding. | ||||||||||||||||||||||||||||||||||||||||||||||
| (l) | Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. | ||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Net (Loss) Income and EPS | |||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
| (DOLLARS IN MILLIONS) | (Loss) income before taxes | Provision for income taxes (o) | Net (loss) income attributable to IFF (p) | Diluted EPS | Income before taxes | Provision for income taxes (o) | Net income attributable to IFF (p) | Diluted EPS | |||||||||||||||||||||||||||||||||||||||
| Reported (GAAP) | $ | (1,625) | $ | 239 | $ | (1,871) | $ | (7.32) | $ | 354 | $ | 75 | $ | 270 | $ | 1.10 | |||||||||||||||||||||||||||||||
| Acquisition Related Costs (a) | (4) | — | (4) | (0.02) | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Restructuring and Other Charges | 12 | 2 | 10 | 0.04 | 41 | 9 | 32 | 0.13 | |||||||||||||||||||||||||||||||||||||||
| Losses (Gains) on Sale of Fixed Assets | (3) | (1) | (2) | (0.01) | (1) | — | (1) | — | |||||||||||||||||||||||||||||||||||||||
| Impairment of Goodwill (b) | 2,250 | — | 2,250 | 8.81 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Impairment of Long-Lived Assets (c) | 120 | 24 | 96 | 0.38 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Shareholder Activism Related Costs (d) | 3 | 1 | 2 | 0.01 | 7 | 2 | 5 | 0.02 | |||||||||||||||||||||||||||||||||||||||
| Business Divestiture Costs (e) | 110 | (64) | 174 | 0.68 | 42 | 10 | 32 | 0.12 | |||||||||||||||||||||||||||||||||||||||
| Gains on Business Disposal | (11) | (96) | 85 | 0.34 | (13) | (14) | 1 | 0.01 | |||||||||||||||||||||||||||||||||||||||
| Employee Separation Costs (f) | 11 | 1 | 10 | 0.04 | 29 | 2 | 27 | 0.11 | |||||||||||||||||||||||||||||||||||||||
| Strategic Initiative Costs (g) | 3 | 1 | 2 | 0.01 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Global Shared Services Implementation Costs (h) | 5 | 1 | 4 | 0.01 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Pension Income Adjustment (i) | — | — | — | — | (17) | (4) | (13) | (0.05) | |||||||||||||||||||||||||||||||||||||||
| Pension Settlement (j) | — | — | — | — | 2 | — | 2 | 0.01 | |||||||||||||||||||||||||||||||||||||||
| Frutarom Acquisition Related Costs (k) | 1 | — | 1 | — | 2 | — | 2 | 0.01 | |||||||||||||||||||||||||||||||||||||||
| N&B Inventory Step-Up Costs | — | — | — | — | 368 | 79 | 289 | 1.19 | |||||||||||||||||||||||||||||||||||||||
| N&B Transaction Related Costs (l) | — | — | — | — | 91 | 19 | 72 | 0.29 | |||||||||||||||||||||||||||||||||||||||
| Integration Related Costs (m) | 94 | 23 | 71 | 0.28 | 105 | 24 | 81 | 0.33 | |||||||||||||||||||||||||||||||||||||||
| Redemption value adjustment to EPS (n) | — | — | — | (0.01) | — | — | — | 0.01 | |||||||||||||||||||||||||||||||||||||||
| Adjusted (Non-GAAP) | $ | 966 | $ | 131 | $ | 828 | $ | 3.24 | $ | 1,010 | $ | 202 | $ | 799 | $ | 3.28 | |||||||||||||||||||||||||||||||
| Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization | |||||||||||
| Year Ended December 31, | |||||||||||
| (DOLLARS AND SHARE AMOUNTS IN MILLIONS) | 2022 | 2021 | |||||||||
| Numerator | |||||||||||
| Adjusted (Non-GAAP) Net Income | $ | 828 | $ | 799 | |||||||
| Amortization of Acquisition related Intangible Assets | 727 | 732 | |||||||||
| Tax impact on Amortization of Acquisition related Intangible Assets (o) | 170 | 158 | |||||||||
| Amortization of Acquisition related Intangible Assets, net of tax (q) | 557 | 574 | |||||||||
| Adjusted (Non-GAAP) Net Income ex. Amortization | $ | 1,385 | $ | 1,373 | |||||||
| Denominator | |||||||||||
| Weighted average shares assuming dilution (diluted) | 255 | 244 | |||||||||
| Adjusted (Non-GAAP) EPS ex. Amortization | $ | 5.42 | $ | 5.63 | |||||||
| (a) | Represents costs related to the acquisition of Health Wright Products, primarily consulting and legal fees, offset in part by earn out adjustments. | ||||||||||||||||||||||||||||||||||||||||||||||
| (b) | Represents costs related to the impairment of goodwill in the Health & Biosciences reporting unit. | ||||||||||||||||||||||||||||||||||||||||||||||
| (c) | Represents costs related to the impairment of intangible and fixed assets of an asset group that operates primarily in Russia. | ||||||||||||||||||||||||||||||||||||||||||||||
| (d) | Represents shareholder activist related costs, primarily professional fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (e) | Represents costs, including establishment of deferred tax liabilities, related to the Company's sales and planned sales of businesses, primarily legal and professional fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (f) | Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company. | ||||||||||||||||||||||||||||||||||||||||||||||
| (g) | Represents costs related to the Company's strategic assessment and business portfolio optimization efforts, primarily consulting fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (h) | Represents costs related to the Company's efforts of restructuring the Global Shared Services Centers, primarily consulting fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (i) | Represents catch-up of net pension income from prior periods that had been excluded from their respective periods. | ||||||||||||||||||||||||||||||||||||||||||||||
| (j) | Represents pension settlement charges incurred in one of the Company's UK pension plans. | ||||||||||||||||||||||||||||||||||||||||||||||
| (k) | Represents transaction-related costs and expenses related to the acquisition of Frutarom, primarily includes earn-out payments, net of adjustments. | ||||||||||||||||||||||||||||||||||||||||||||||
| (l) | Represents transaction costs and expenses related to the transaction with N&B, primarily legal and professional fees. | ||||||||||||||||||||||||||||||||||||||||||||||
| (m) | Represents costs related to integration activities since 2018, primarily for Frutarom and N&B. For 2022, represents costs primarily related to external consulting fees and internal integration costs, including salaries of individuals who are fully dedicated to integration efforts. For 2021, represents costs primarily related to performance stock awards and consulting fees for advisory services. | ||||||||||||||||||||||||||||||||||||||||||||||
| (n) | Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable non-controlling interests over their existing carrying value. | ||||||||||||||||||||||||||||||||||||||||||||||
| (o) | The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments. | ||||||||||||||||||||||||||||||||||||||||||||||
| (p) | For 2022, net loss is increased by income attributable to non-controlling interest of $7 million. For 2021, net income is reduced by income attributable to non-controlling interest of $9 million. | ||||||||||||||||||||||||||||||||||||||||||||||
| (q) | Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. | ||||||||||||||||||||||||||||||||||||||||||||||
M-8?20$3;8T.P6BP^0"X99K>]9!:G